Catheter Precision CEO granted 40,000 stock options
Catheter Precision, Inc. reported that Chairman and CEO David A. Jenkins received a grant of options to buy 40,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Catheter Precision, Inc. reported that Chairman and CEO David A. Jenkins received a grant of options to buy 40,000 shares of common stock. The options have an exercise price of $1.15 per share, expire on March 26, 2036, and vest 100% 180 days after the grant date.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Options (Right to Buy) | 40,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. Options vest 100% on 180 day anniversary of grant date.
Key Figures
Key Terms
Options (Right to Buy) financial
exercise price financial
expiration date financial
underlying security financial
vest 100% on 180 day anniversary financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Catheter Precision (VTAK) report for David A. Jenkins?
What is the exercise price of the new options granted to the VTAK CEO?
When do the Catheter Precision (VTAK) CEO’s options vest and become exercisable?
When do the newly granted VTAK CEO options expire?
AI-generated analysis. How Rhea-AI works. Not financial advice.